BE Study of Gaster®D Tab 20mg (Manufacturer Changed)

Summary

An Open-Label, Randomized, Two-sequence, Two-period, Fasting Condition, Single Oral Dose, Cross-over Study of Bioequivalence of "Gaster®D Tab20mg (Famotidine) (Changed Manufacturer)" and "Gaster®D Tab 20mg (Famotidine) (Unchanged Manufacturer, Announced Reference Drug)" in Healthy, Adult, Human Subjects.

Timeline

Start

2019-10-11

Primary completion

2019-11-21

Completion

2020-01-03

Drugs

Indications